Request Demo

Last update 08 May 2025

Etozolin

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Etozolin (USAN/INN)

+ [5]

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesOther Diseases

Active Indication

EdemaHypertension

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC13H20N2O3S

InChIKeyZCKKHYXUQFTBIK-UHFFFAOYSA-N

CAS Registry73-09-6

100 Clinical Results associated with Etozolin

100 Translational Medicine associated with Etozolin

100 Patents (Medical) associated with Etozolin

110

Literatures (Medical) associated with Etozolin

01 Jan 2024·Chromatographia

Comparative Study of Cellulose Tris(3-chloro-5-methylphenylcarbamate) Coated or Covalently Immobilized on Silica for the Separation of Enantiomers in High-Performance Liquid Chromatography

Author: Khatiashvili, Tamar ; Karchkhadze, Marina ; Matarashvili, Iza ; Farkas, Tivadar ; Chankvetadze, Bezhan

In the present study, a comparison was performed between chiral stationary phases (CSPs) prepared by coating or covalent immobilization of cellulose tris(3-chloro-5-methylphenylcarbamate) onto silica.The columns were evaluated in HPLC separation of enantiomers of various acidic, basic, and neutral chiral analytes in acetonitrile, methanol, and mixtures of n-hexane and propan-2-ol as mobile phases.A difference in enantiomer-resolving ability of coated and covalently immobilized CSs was observed

14 Jun 2022·ACS Omega

Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies

Article

Author: Kloczkowski, Andrzej ; Yasir, Muhammad ; Shahzadi, Saba ; Hassan, Mubashir

Novel drug development is a time-consuming process with relatively high debilitating costs. To overcome this problem, computational drug repositioning approaches are being used to predict the possible therapeutic scaffolds against different diseases. In the current study, computational drug repositioning approaches were employed to fetch the promising drugs from the pool of FDA-approved drugs against Ewing sarcoma. The binding interaction patterns and conformational behaviors of screened drugs within the active region of Ewing sarcoma protein (EWS) were confirmed through molecular docking profiles. Furthermore, pharmacogenomics analysis was employed to check the possible associations of selected drugs with Ewing sarcoma genes. Moreover, the stability behavior of selected docked complexes (drugs-EWS) was checked by molecular dynamics simulations. Taken together, astemizole, sulfinpyrazone, and pranlukast exhibited a result comparable to pazopanib and can be used as a possible therapeutic agent in the treatment of Ewing sarcoma.

01 Jan 2021·Computational and Structural Biotechnology JournalQ3 · BIOLOGY

Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case study

Q3 · BIOLOGY

ArticleOA

Author: Hatmal, Ma'mon M ; Taha, Mutasem ; Abuyaman, Omar

In the present work we introduce the use of multiple docked poses for bootstrapping machine learning-based QSAR modelling. Ligand-receptor contact fingerprints are implemented as descriptor variables. We implemented this method for the discovery of potential inhibitors of the serine protease enzyme TMPRSS2 involved the infectivity of coronaviruses. Several machine learners were scanned, however, Xgboost, support vector machines (SVM) and random forests (RF) were the best with testing set accuracies reaching 90%. Three potential hits were identified upon using the method to scan known untested FDA approved drugs against TMPRSS2. Subsequent molecular dynamics simulation and covalent docking supported the results of the new computational approach.

100 Deals associated with Etozolin

External Link

KEGG	Wiki	ATC	Drug Bank
D04111	Etozolin	C03CX01	DB08982

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Edema	-	-	-
Hypertension	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESH1989	Not Applicable	Essential Hypertension	1,337	Etozolin 200 mg once a day	huadxebwib(symdmzbezi) = zoouplbadc ugdbhqkqws (xdgnkjvunm ) View more	Positive	18 Mar 1989
				Etozolin + Verapamil	(rzmdyroutn) = tsqeawjonp ntuskidtuh (bmwaoknfqz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Etozolin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation